Latest Breaking News On - நிறுவனம் தி கண்டுபிடிப்பாளர் - Page 1 : comparemela.com
Article content
Share“) of the Company and one common share purchase warrant (a “
Warrant“). Each Warrant will entitle the holder to purchase one additional Share of the Company at a price of $0.40 per Share for a period of twelve (12) months from the date of closing. The Warrants are subject to an acceleration clause in the event the trading price of the Shares equals or exceeds $0.50 per Share for a period of ten (10) consecutive days.
The Company intends to pay finder’s fees in connection with the Private Placement to certain eligible finders in the form of: (i) a cash commission of 7.0% of the gross proceeds raised under the Private Placement from investors introduced to the Company by the finder; and (ii) the issuance of such number of non-transferable common share purchase warrants of the Company (the “
Canada
United-kingdom
Cranbrook
Kent
British
Canadian
Jim-stypula
Ian-gendall
Robin-sudo
Company-the-units
Company-the-finder
Newsfile-corp
DLP Resources Inc.: DLP Resources Announces Non-Brokered Private Placement to be Made Available to Existing Shareholders
DLP Resources Inc.
DLP or the
Company ) announces that, further to its news release dated May 18, 2021, the Company intends to make its previously announced non-brokered private placement of up to 6,666,667 units of the Company (the
Units ) at a price of $0.30 per Unit (the
Private Placement ) available to existing shareholders of the Company who, as of the close of business on May 18, 2021, held common shares of the Company (and who continue to hold such common shares as of the closing date), pursuant to the prospectus exemption set out in BC Instrument 45-534 -
Canada
United-kingdom
Cranbrook
Kent
British
Canadian
Jim-stypula
Kostenloser-wertpapierhandel
Ian-gendall
Robin-sudo
Company-the-units
Company-the-finder
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE)
Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce that it has completed the acquisition (the “Transaction”) of Akome Biotech Ltd. (“Akome”). With this strategic acquisition, the scope of Core One’s psychedelics’ bio-pharma research and development division will broaden to include drug formulations that effectively target and change underlying processes at the root of neurological disorders, and/or prevent further neurological damage that result from the disorders.
United-states
Canada
United-kingdom
Vancouver
British-columbia
British
Canadian
Joel-shacker
Company-the-finder
Company-or-core-one
Trademark-office
Core-one-labs-inc
vimarsana © 2020. All Rights Reserved.